Marketing and pharmacoeconomic studies of statin drugs
DOI:
https://doi.org/10.24959/nphj.25.177Keywords:
pharmaceutical market, marketing research, pharmacoeconomic research, hypolipidemic drugs, availability of drugsAbstract
Aim. To conduct a marketing and pharmacoeconomic analysis of statin drugs and study consumption trends of this group of drugs based on sales indicators from pharmacies.
Materials and methods. The paper used methods of desk marketing research, economic and statistical method, methods of pharmacoepidemiological and pharmacoeconomic research (formal VN-analysis, cost minimization method). Consumption of monocomponent statin drugs was studied according to sales data for 2024 at 1746 pharmacies, which are part of three pharmacy chains. The physical availability of statins was studied according to penetration indicators in pharmacies, economic availability — according to the solvency adequacy ratio.
Results and their discussion. The State Register found 253 records of registration of statins with the following INNs: simvastatin, atorvastatin, rosuvastatin, and pitavastatin. The largest number of drugs, trade names, domestic and foreign manufacturers are represented in the rosuvastatin and atorvastatin segment. Simvastatin drugs are represented by only one domestic manufacturer, and there are no domestic pitavastatin drugs on the market. According to the results of the formal VN analysis, only simvastatin belongs to category V, which is present in all analyzed regulatory and medical-technological documents. Simvastatin, which consumers can receive with reimbursement, occupies only 18.11% in terms of the number of DDs sold. The largest share in statin consumption by DD is occupied by rosuvastatin (56.31%) and atorvastatin (25.39%). All simvastatin drugs have high economic availability for the population; among atorvastatin and rosuvastatin drugs, there are drugs with both high and medium economic availability; all pitavastatin drugs have medium economic availability. Among the simvastatin, atorvastatin, and rosuvastatin drugs, most DDs released belong to foreign manufacturers.
Conclusions. The Ukrainian statin market has revealed a predominance of foreign manufacturers in terms of the number of registered drugs, trade names, and the share of DDs sold from pharmacies. The drugs that lead in sales volume, in most cases, have high physical availability, but are not the cheapest treatment options. Currently, there is a possibility of reimbursement for the cost of treatment only with simvastatin, which is classified as a low-effective statin. Ukrainian consumers can choose atorvastatin and rosuvastatin drugs from domestic and foreign manufacturers in a wide price range (except for certain dosages), however, some drugs with high economic availability have very low penetration rates in pharmacies. The low physical availability of the only domestic drug of the simvastatin group and the lack of domestic drugs of the pitavastatin group may limit patients' access to more affordable treatment options. The high proportion of consumption of rosuvastatin and atorvastatin, which are not subject to reimbursement, makes it urgent to expand the reimbursement program to increase access to modern statin therapy for more patients.
References
World heart report 2023: confronting the world’s number one killer. World Heart Federation, 2023. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://world-heart-federation.org/wp-content/uploads/World-Heart-Report-2023.pdf.
Nedkoff, L., Briffa, T., Zemedikun, D., Herrington, S., & Wright, L. (2023). Global trends in atherosclerotic cardiovascular disease. Clinical Therapeutics, 45, 1087-1091. https://doi.org/10.1016/j.clinthera.2023.09.020.
Nemchenko, A. S., Popova, I. A., & Demchenko, N. V. (2024). Doslidzhennia farmatsevtychnoho zabezpechennia khvorykh na sertsevo-sudynni zakhvoriuvannia v ramkakh prohramy «Dostupni liky». Health & Education, 1, 121-130. https://doi.org/10.32782/health-2024.1.16.
Chou, R., Dana, T., Blazina, I., Daeges, M., & Jeanne, T. L. (2016). Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US Preventive Services Task Force. JAMA, 316(19), 2008-2024. https://doi.org/10.1001/jama.2015.15629.
Almeida, S. O., & Budoff, M. (2019). Effect of statins on atherosclerotic plaque. Trends Cardiovasc Med, 29 (8), 451-455. https://doi.org/10.1016/j.tcm.2019.01.001.
Nakaz MOZ Ukrainy «Profilaktyka sertsevo-sudynnykh zakhvoriuvan. Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy» № 564 (2016, cherven 13). chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.dec.gov.ua/wp-content/uploads/2019/11/2016_564_ykpmd_pssz.pdf.
Kosuiev, H. I. (2021) Suchasni hrani statynoterapii u praktytsi simeinoho likaria: zapytannia ta vidpovidi. Zdorov’ia Ukrainy 21 storichchia, 4 (497), 12-14.
Dumenko, T. M., Parii, V. D., Yakovlieva, L. B., & Zimenkovskyi, A. B. (2013) Vyvchennia dostupnosti osnovnykh likarskykh zasobiv v Ukraini: rezultaty spilnoho proektu VOZ, NAI ta MOZ Ukrainy. Farmakoekonomika v Ukraini: stan ta perspektyvy (s. 180-281). Natsionalnyi farmatsevtychnyi universytet.
Bezditko, N. V., Mishchenko, O. Ya., Chynush, I. V., Adonkina, V. Yu., & Bondarchuk, I. S. (2014).Nevykorystani mozhlyvosti: farmakoepidemiolohichnyi analiz dynamiky spozhyvannia preparativ statyniv v Ukraini. Klinichna farmatsiia, (2), 62-65.
Tkachova, O. V., & Bohatyrchuk, L. P. (2016) Statyny: doslidzhennia asortymentu ta sotsialno-ekonomichnoi dostupnosti dlia ukrainskykh patsiientiv. Suchasni napriamky udoskonalennia farmatsevtychnoho zabezpechennia naselennia na rehionalnomu rivni (s. 35-43).
Yevtushenko, O. M., Nemtsova, V. D., & Chaikovska, V. V. (2019). Statyny: farmakoekonomichni aspekty zastosuvannia preparativ hrupy inhibitoriv HMH-KoA-reduktazy. Klinichna farmatsiia, 23(1), 46-55. https://doi.org/10.24959/cphj.19.1476.
Derzhavnyi reiestr likarskykh zasobiv Ukrainy. http://www.drlz.com.ua/ibp/ddsite.nsf/all/shlist?opendocument.
Derzhavnyi formuliar likarskykh zasobiv. Vypusk shistnadtsiatyi (2024). chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://moz.gov.ua/uploads/10/54241-dn_418_12032024_dod.pdf.
Postanova KMU «Deiaki pytannia derzhavnoho rehuliuvannia tsin na likarski zasoby i vyroby medychnoho pryznachennia» № 333 (2009, Berezen 25). https://zakon.rada.gov.ua/laws/show/333-2009-%D0%BF#Text.
Nakaz MOZ Ukrainy «Pro zatverdzhennia Perelikiv likarskykh zasobiv i medychnykh vyrobiv, yaki pidliahaiut reimbursatsii za prohramoiu derzhavnykh harantii medychnoho obsluhovuvannia naselennia, stanom na 23 serpnia 2024 r.» (2024, Veresen 04). https://surl.li/hdlxxx.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
